---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-002721"
form_type: "8-K"
ticker: "VCEL"
cik: "0000887359"
company_name: "Vericel Corp"
filed_at: "2023-01-10T23:59:59+00:00"
generated_at: "2026-06-20T17:22:10.314970+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vericel prelim FY2022 rev ~$164-165M; MACI arthro launch accelerated to 2024; NexoBrid approved

## Summary
- Full-year 2022 total revenue expected ~$164-165M; MACI rev ~$132M at high end of guidance.
- Q4 MACI revenue growth ~24% YoY; 10th straight quarter of positive adjusted EBITDA and operating cash flow.
- Cash and investments ~$140M, no debt as of Dec 31, 2022.
- NexoBrid FDA approved Dec 28, 2022 for eschar removal in thermal burns; U.S. commercial launch expected Q2 2023.
- MACI arthroscopic delivery human factors study planned for 2023; commercial launch now expected in 2024.

## SEC filing metadata
- accession: 0001104659-23-002721
- form_type: 8-K
- ticker: VCEL
- cik: 0000887359
- company_name: Vericel Corp
- filed_at: 2023-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/887359/000110465923002721/0001104659-23-002721-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/887359/000110465923002721/tm232747d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-002721
- JSON: https://secwatch.observer/filing/0001104659-23-002721.json
- Plain text: https://secwatch.observer/filing/0001104659-23-002721.txt

## Key facts
- Earnings Releases
  Vericel Corp reported the year ended December 31, 2022 results: revenue approximately $164 to $165 million.
  - Period: the year ended December 31, 2022
  - Revenue: approximately $164 to $165 million
  - Result: preliminary results
  source text: Total net revenue for full-year 2022 expected to be approximately $164 to $165 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/887359/000110465923002721/0001104659-23-002721-index.htm
- Earnings Releases
  Vericel Corp reported preliminary financial results for the fourth quarter ended December 31, 2022.
  - Period: the fourth quarter ended December 31, 2022
  - Result: preliminary results
  source text: Fourth quarter MACI revenue growth expected to be approximately 24% versus prior year
  evidence_url: https://www.sec.gov/Archives/edgar/data/887359/000110465923002721/0001104659-23-002721-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.